| Identification | Back Directory | [Name]
Ergosta-2,24-dien-26-oic acid, 5,6-epoxy-22,27-dihydroxy-1-oxo-4-[(2-pyridinylcarbonyl)oxy]-, δ-lactone, (4β,5β,6β,22R)- | [CAS]
2690312-67-3 | [Synonyms]
ASR-490
Ergosta-2,24-dien-26-oic acid, 5,6-epoxy-22,27-dihydroxy-1-oxo-4-[(2-pyridinylcarbonyl)oxy]-, δ-lactone, (4β,5β,6β,22R)- | [Molecular Formula]
C34H41NO7 | [MOL File]
2690312-67-3.mol | [Molecular Weight]
575.7 |
| Chemical Properties | Back Directory | [Boiling point ]
760.1±60.0 °C(Predicted) | [density ]
1.30±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
13.66±0.10(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
ASR-490 reduces the viability of HCT116 and SW620 cells by downregulating Notch1 signaling. ASR-490 overcomes Notch1 overexpression and inhibits the growth of HCT/Notch1 transfectants. ASR-490 inhibits the tumor growth in control (pCMV/HCT116) and Notch1/HCT116 in xenotransplanted mice[1]. | [in vivo]
ASR-490 (5 mg/kg; i.p.; thrice a week for 4 weeks) inhibits the tumor growth in control (pCMV/HCT116) and Notch1/HCT116 in xenotransplanted mice[1]. | Animal Model: | Six- to 8-week-old BALB/c athymic nude mice (nu/nu) (pCMV/HCT116
and Notch1/HCT116 (C4) xenografts)[1]. | | Dosage: | 5 mg/kg | | Administration: | i.p., thrice a week for 4 weeks | | Result: | Inhibited the tumor growth in control (pCMV/HCT116) and Notch1/HCT116 in xenotransplanted mice. |
| [References]
[1] Tyagi A, et al. ASR490, a Small Molecule, Overrides Aberrant Expression of Notch1 in Colorectal Cancer. Mol Cancer Ther. 2020; 19(12):2422-2431. DOI:10.1158/1535-7163.MCT-19-0949 |
|
|